Fig. 3
Illness severity scores, distributions of organ failures and pathogens, and outcomes stratified by immune subtypes. a–c Modified Early Warning Score, Universal Vital Assessment score, modified systemic inflammatory response syndrome [mSIRS], and quick Sepsis-related Organ Failure assessment [qSOFA] scores stratified by immune subtype in the discovery cohort; p-values in 3C represent Chi-squared test with continuity correction (N = 201). d Chord plot indicating proportion of patients with specific organ failures across each subtype in the discovery cohort; a wider chord band indicates a greater proportion of patients with each corresponding organ failure (N = 201, proportions in subtype 2 vs. 1 as follows: shock: 17.7% vs. 10.5%; acute respiratory failure: 21.9% vs. 17.1%; severe anemia: 26.0% vs. 13.3%; encephalopathy: 25.0% vs. 15.2%). e Chord plot indicating proportion of patients with specific infections across each subtype in the discovery cohort; a wider chord band indicates a greater proportion of patients with each corresponding infection (N = 201, proportions in subtype 2 vs. 1 as follows: HIV: 65.6% vs. 42.0%, tuberculosis: 27.1% vs. 8.6%, malaria: 24.5% vs. 14.6%, influenza: 4.5% vs. 10.5%). f Proportions of patients with known HIV-infection status (N = 199), HIV-associated TB (N = 199), and positive urine TB-LAM results (among those tested, N = 83) across each immune subtype in the discovery cohort. g In-hospital outcome (N = 288), impaired functional status [Karnofsky Performance Status; KPS] among hospital survivors (N = 246), and 30-day vital status (N = 260) across each subtype in a pooled cohort of patients from the discovery and internal validation cohorts; p-values in 3F and 3G represent Chi-squared test with continuity correction. h Forest plot indicating univariable (unadjusted) odds ratios for in-hospital outcome and 30-day mortality among patients in subtype 2 vs. subtype 1, stratified by key pathogen groups in pooled discovery and internal validation cohort [patients with influenza omitted given small number of events in that pathogen group; for visualization, upper limit of 95% confidence interval for 30-day mortality truncated at 15 for patients with malaria (upper limit 27.57)